期刊文献+

Assay method for quality control and stability studies of a new antimalarial agent (CDRI 99/411)

Assay method for quality control and stability studies of a new antimalarial agent (CDRI 99/411)
下载PDF
导出
摘要 CDRI compound no. 99/411 is a potent 1,2,4-trioxane antimalarial candidate drug under development at our Institute. An HPLC method for determination of CDRI 99/411 with its starting material and intermediates has been developed and validated for in process quality control and stability studies. The analytical performance parameters such as linearity, precision, accuracy, specificity, limit of detection (LOD) and lower limit of quantification (LLOQ) were determined according to International Conference on Harmonization ICH Q2(R1) guidelines. HPLC separation was achieved on a RP-select B Lichrosphere~ column (250 mm x 4 ram, 5 lam, Merck) using water containing 0.1% glacial acetic acid and acetonitrile as the mobile phase in a gradient elution. The eluents were monitored by a photo diode array detector at 245 and 275 nm. Based on signal to noise ratio of 3 and 10 the LOD of CDRI 99/411 was 0.55 μg/mL, while the LLOQ was 1.05 μg/mL. The calibration curves were linear in the range of 1.05- 68 μg/mL. Precision of the method was determined by inter- and intra-assay variations within the acceptable range. CDRI compound no. 99/411 is a potent 1,2,4-trioxane antimalarial candidate drug under development at our Institute. An HPLC method for determination of CDRI 99/411 with its starting material and intermediates has been developed and validated for in process quality control and stability studies. The analytical performance parameters such as linearity, precision, accuracy, specificity, limit of detection (LOD) and lower limit of quantification (LLOQ) were determined according to International Conference on Harmonization ICH Q2(R1) guidelines. HPLC separation was achieved on a RP-select B Lichrosphere~ column (250 mm x 4 ram, 5 lam, Merck) using water containing 0.1% glacial acetic acid and acetonitrile as the mobile phase in a gradient elution. The eluents were monitored by a photo diode array detector at 245 and 275 nm. Based on signal to noise ratio of 3 and 10 the LOD of CDRI 99/411 was 0.55 μg/mL, while the LLOQ was 1.05 μg/mL. The calibration curves were linear in the range of 1.05- 68 μg/mL. Precision of the method was determined by inter- and intra-assay variations within the acceptable range.
出处 《Journal of Pharmaceutical Analysis》 SCIE CAS 2013年第5期335-340,共6页 药物分析学报(英文版)
基金 Financial support to Shakti Deep Pachauri and Kiran Khandelwal from the Council of Scientifc and Industrial Research (CSIR)New Delhi India is gratefully acknowledged
关键词 HPLC TRIOXANE Process quality control STABILITY HPLC Trioxane Process quality control Stability
  • 相关文献

参考文献1

二级参考文献9

  • 1M J O'Neil. The Merck Index[M].Merck Research Laboratories,Whitehouse Station,NJ,2006.
  • 2M J McLean,M Schmutz,M Pozza. The influence of rufinamide on sodium currents and action potential firing in rodent neurons[abstract no 3 062][J].Epilepsia,2005,(Suppl 6):S375.
  • 3L A Brunner,M L Powell. An automated method for the determination of a new potential antiepileptic agent(CGP 33101)in human plasma using high performance liquid chromatography[J].Biomedical Chromatography,1992,(06):278-282.
  • 4M C Rouan,C Souppart,L Alif. Automated analysis of a novel anti-epileptic compound,CGP 33,101,and its metabolite,CGP 47,292,in body fluids by high-performance liquid chromatography and liquid-solid extraction[J].Journal of Chromatography B:Biomedical Sciences and Applications,1995,(02):307-313.
  • 5M C Rouan,C Buffet,L Masson. Practice of solid-phase extraction and protein precipitation in the 96-well format combined with high-performance liquid chromatography-ultraviolet detection for the analysis of drugs in plasma and brain[J].Journal of Chromatography B:Biomedical Sciences and Applications,2001,(01):45-55.
  • 6M Contin,S Mohamed,C Candela. Simultaneous HPLC-UV analysis of rufmamide,zonisamide,lamotrigine,oxcarbazepinemonohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy[J].Journal of Chromatography B:Analytical Technologies in the Biomedical and Life Sciences,2010,(3-4):461-465.
  • 7M Iolanda,R Manuela,F Cinzia. Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva[J].Analytical Biochemistry,2011,(03):1013-1021.
  • 8M Giancarlo la,M Sabrina,F Luca. Rapid assay of rufinamide in dried blood spots by a new liquid chromatographytandem mass spectrometric method[J].Journal of Pharmaceutical and Biomedical Analysis,2011,(01):192-197.
  • 9S Muneer,C Jose Gnana Babu,R Hakeem. Development and validation of RP-HPLC method for estimation of rufinamide in bulk and its pharmaceutical dosage form[J].Int J Pharm Res Anal,2012,(01):9-13.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部